I am writing this letter to urge the readers to notice a potential problem in the near future regarding the management of osteoporosis in the Asian region.

In the June issue of Osteoporosis and Sarcopenia, Benjamin et at. published an article entitled "Review on the comparison of effectiveness between bisphosphonate and denosumab in postmenopausal women", the results are clear, and apparently we have a treatment option which probably is more effective than the bisphosphonates [@bib1]. On the other hand, Khosla of the Mayo Clinic almost at the same time, published an editorial on *J Bone Miner Res* entitled "A crisis in the treatment of osteoporosis", claiming for a more positive attitude toward treating osteoporosis patients with effective medications [@bib2]. He quoted a stunning decrease in the usage rate of bisphosphonate in osteoporotic patients after their hip fractures, from 15% in 2004 to 3% in 2013. The main reason seems to be the concern about the rare side effects of bisphosphonates and other antiresorptives, namely osteonecrosis of the jaw (ONJ), and an even less common side effect, atypical femur fracture (AFF). We and others in Asia have surveyed the incidence rate of ONJ after bisphosphonate treatment in the general population and large medical centers [@bib3]. The rate we found in Taiwan was 0.5% per year after the first year. Japanese colleague reported a similar rate [@bib4]. These rates are slightly higher than that reported in the Caucasian population, but are in general quite low. As in the report of Khosla, the treatment benefit should still outweigh the risk of the side effects of bisphosphonates. Denosumab is widely available in Asia while the rates of the side effects after its usage have not been systematically surveyed. The anecdotal impression was that this rates seems to be similar of less than that of the bisphosphonates.

I would like to propose that a systematic survey of ONJ and AFF after denosumab treatment be performed in Asian countries, and the benefit and risk of bisphosphonate and denosumab treatment for osteoporosis be analyzed. Then the Asian osteoporosis societies may explain this issue clearly to the general population. The medical personnels of course should and will use the appropriate treatment to manage the osteoporotic patients in their countries with more confidence. After all we have to avoid the situation of "to fail our patients" as mentioned in the article of Khosla.
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